148 related articles for article (PubMed ID: 27784457)
1. [Clinical significance of expression of PI3Kp110α in breast cancer].
Xiong Y; Si JW; Li D; Wang Y; Qu LL; Zhang H; Zhang B; Li T
Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):743-749. PubMed ID: 27784457
[No Abstract] [Full Text] [Related]
2. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma.
Lucarelli AP; Martins MM; Montor W; Oliveira V; Galvão MA; Piato S
Sao Paulo Med J; 2011 Dec; 129(6):371-9. PubMed ID: 22249792
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C alpha expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma.
Ainsworth PD; Winstanley JH; Pearson JM; Bishop HM; Garrod DR
Eur J Cancer; 2004 Oct; 40(15):2269-73. PubMed ID: 15454252
[TBL] [Abstract][Full Text] [Related]
5. Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations.
Wang S; Li W; Lv S; Wang Y; Liu Z; Zhang J; Liu T; Niu Y
Histopathology; 2011 Oct; 59(4):631-42. PubMed ID: 22014044
[TBL] [Abstract][Full Text] [Related]
6. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Oliveira VM; Piato S; Silva MA
Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance and mechanism of upregulation of PI3Kp110α in non-small cell lung carcinoma].
Xiong Y; Qu LL; Li D; Wang Y; Li T
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):737-743. PubMed ID: 29061016
[No Abstract] [Full Text] [Related]
8. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
9. [Aromatase expression in invasive and in situ ductal carcinoma present in the same breast].
Oliveira VM; Ribeiro Lde S; Rossi LM; Silva MA; Aldrighi JM; Bagnoli F; Rinaldi JF; Aoki T
Rev Assoc Med Bras (1992); 2009; 55(6):651-5. PubMed ID: 20191218
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activity in ductal carcinoma in situ of the breast.
Shpitz B; Zimlichman S; Zemer R; Bomstein Y; Zehavi T; Liverant S; Bernehim J; Kaufman Z; Klein E; Shapira Y; Klein A
Breast Cancer Res Treat; 1999 Nov; 58(1):65-9. PubMed ID: 10634519
[TBL] [Abstract][Full Text] [Related]
11. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
13. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer.
Yu BH; Li BZ; Zhou XY; Shi DR; Yang WT
Diagn Pathol; 2018 May; 13(1):36. PubMed ID: 29848352
[TBL] [Abstract][Full Text] [Related]
15. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.
Oka K; Suzuki T; Onodera Y; Miki Y; Takagi K; Nagasaki S; Akahira J; Ishida T; Watanabe M; Hirakawa H; Ohuchi N; Sasano H
Int J Cancer; 2011 Apr; 128(8):1770-82. PubMed ID: 20533549
[TBL] [Abstract][Full Text] [Related]
16. 14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression.
Wan D; Zhang Y; Yu Q; Li F; Zhuo J
Pathol Res Pract; 2021 Nov; 227():153619. PubMed ID: 34560418
[TBL] [Abstract][Full Text] [Related]
17. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of TPL2 may be a predictor of good prognosis in patients with breast invasive ductal carcinoma.
Yu Q; Wan D; Fu R; Li F; Zhang Y
Sci Rep; 2023 Oct; 13(1):17346. PubMed ID: 37833434
[TBL] [Abstract][Full Text] [Related]
19. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
20. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
Wong H; Lau S; Leung R; Chiu J; Cheung P; Wong TT; Liang R; Epstein RJ; Yau T
Med Oncol; 2012 Sep; 29(3):1536-42. PubMed ID: 21983862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
